

# Your **VISION**, Our **FUTURE** Korean Medical Device




Ministry of Food and  
Drug Safety




# 01. Passion for Growth Excellence

Korea's medical device market ranks as the ninth largest in the world at an estimated 6.8 billion USD in 2018, showing continuous growth with 8.1% annual increase.

### Korean MD Market Size



### Korean MD Companies




As producers of world class technology, Korean medical device manufactures are attempting to export to the global medical devices market whose safety and effectiveness have been proven by Ministry of Food and Drug Safety (MFDS).

### Major Exports of Korean Medical Devices in 2018

Ranking	Top10 Exports
1	Ultrasound Imaging system
2	Biomaterial Graft/Prosthesis
3	Soft Contact Lens
4	Dental Implant
5	IVD Reagents for Self-testing
6	IVD Reagents for Infectious Disease
7	Dental X-ray System
8	Medical Image, Analog to Digital Transform, DR, CR
9	IVD Reagents for HIV, HBV, HCV, HTLV
10	Dental Implant Superstructure

Korea has become a clinical trial powerhouse for various innovative medical devices with the accelerated clinical trial approval system and ISO 14155 compliance.

### Clinical Trial Approvals



There are a total of 166 clinical trial centers designated by MFDS, providing diverse and robust environments for clinical trials.


### Clinical Trial Centers






## 02. Internationally Aligned Medical Device Regulatory System

Korean regulatory systems, harmonized with the global regulations, allow MFDS to manage the medical devices more effectively.



MFDS has an efficient and well-balanced system to manage the overall lifecycle of medical devices




For Class 4 devices with higher risks, UDI system will reinforce the whole management of medical devices

- ▶ UDI System allows us to manage UDI information, related information, information of the manufacturer and importer
- ▶ The starting date of UDI in each class

	Class 4 (high risk)	Class 3 (serious risk)	Class 2 (potential risk)	Class 1 (lower risk)
Placing UDI	July, 2019	July, 2020	July, 2021	July, 2022

## Mandatory GLP System for Medical Devices


- ▶ To enhance confidence in biological safety testing of medical devices contacting or inserted into human body
- ▶ To reduce time and cost for pre-market approval by mutually accepting GLP study data among OECD-recognized MAD countries when exporting to the other countries





## 03. Strategic Operation based on Expertise & Efficacy

With a systematic organization structure, MFDS is strategically operated for an effective medical device management



MFDS collaborates with external third party organizations to increase efficiency and expertise in controlling medical devices.

### Affiliated Organization



<b>National Institute of Medical Device Safety Information (NIDS)</b>	<b>A legal entity established in 2012</b> <ul style="list-style-type: none"> <li>- Supports and provides with information regarding clinical trials, standards, safety, training, etc.</li> <li>- Issues Notification of Class I devices &amp; Certification of Class II devices</li> </ul>
---	---

### Related Organizations designated by MFDS

<b>Medical Device QMS Audit Institutions</b>	Conduct QMS audit and issuing certificates with MFDS (4 Institutions)
<b>Medical Device Testing Laboratories</b>	Test medical devices (15 Labs)
<b>Technical Document Review Agencies</b>	Review technical documents on class II devices (8 Agencies)
<b>Medical Device Clinical Trial Centers</b>	Hospitals designated by MFDS (166 Centers) Conduct clinical trials for medical devices
<b>GLP Laboratories</b>	Biological Evaluation of medical devices (5 Labs)

## Establishment of Innovative Convergence Products Support Department

- ▶ Background: The need for the whole management of convergence products including innovative medical devices, advanced biopharmaceuticals, and regenerative medicines
- ▶ Organizational structure and its responsibilities






## 04. Special New Acts on Innovative Medical Devices and IVDs

Legislation in support of innovative devices and promotion of the industry

- 1) Designating devices with cutting-edge technologies and even higher safety and effectiveness as innovative medical devices
- 2) Prioritizing the overall review over those of regular devices, and frequent checks for each stage of innovative devices
- 3) Designating companies that are proactively investing in R&D as innovative devices companies and offering the first choice in bidding for government-funded projects



Legislation for In-Vitro Diagnostic (IVD) medical devices


- 1) Definitions and classifications of IVD devices
- 2) Simultaneous review of IVD devices and the corresponding drugs developed in conjunction with the IVD devices
- 3) Establishment of procedures to allow clinical tests only with approval of IRB






## 05. Predictable Approval System with Scientific Approach

Based on risk classification of medical devices, each classes of devices have different pathways for a marketing authorization.



For an easy access and better compliance of regulations, MFDS provides consultations and various guidelines for applicants.

MFDS also gains additional scientific understanding from a pool of external experts as needed, and invests on various R&D projects to increase expertise in review and approval processes.






## 06. Emphasis on Quality: QMS

MFDS Quality Management System (QMS) regulations are made based on ISO 13485.

- ▶ All medical device manufacturers required to comply with QMS regulations if their devices are distributed in Korea
- ▶ On-site audits are mandatory for class 2, 3, and 4 devices manufacturers, but it is elective for class 1 device manufacturers



## Types of Audits

- ▶ Initial audit : An initial audit to approve QMS conformity assurance
- ▶ Periodic audit : After the initial audit, at least one audit will be conducted within 3 years
- ▶ Audit of approval changes : Audits to be conducted if manufacturers notify the change of manufacturing sites
- ▶ Supplementary audit : Audits to be conducted if a product is added from a different product group

## Method of Audit

- ▶ Conducting on-site audits and document review for each product group\* of manufacturing sites

\* Product group : MFDS categorized the products into 26 product groups which use similar raw materials, manufacturing processes and QMS






## 07. Adverse Event Reporting

As a champion economy of APEC, Korea is putting a lot of effort into the harmonization of medical device vigilance in Asia Pacific region.

Medical device manufacturers, importers and distributors are required to report any adverse events and keep those records.


### Medical Device Adverse Event Reporting and Management System




- ▶ All of collected information regarding adverse event reports are being reviewed and analyzed to be used for field safety

## Integrated Medical Device Information System (IMDIS)

### Implementation of IMDIS (by Oct, 2019)



- An electronic data processing system to effectively record and manage information on medical devices from its approval through manufacturing, importing, distributing and the use
- To strengthen supply chain with prompt identification of defective medical devices and market withdrawals






## 08. Monitoring & Tracking System


In order to keep track of patient safety information, MFDS designates 44 types of medical devices that are inserted in the human body for more than a year, or life-supporting devices that can be used in places other than medical institutions.

MFDS collects information about devices and patients from manufacturers and importers to assure the safe use of those devices and prevent medical incidents.



### Revision and Reinforcement of Monitoring and Tracking Systems

- ▶ Creating a tracking system to identify the approval history, distribution channels, stock locations and the quantity of the product on the basis of the UDI system in case of problems on medical devices
- ▶ Creating an ability to halt the sale and distribution of products on the recall list



# List of Medical Devices Subject to Tracking

1. Medical Devices that are inserted in the human body for one year or more

	Medical Devices	date
1	Pacemaker, cardiac, implantable	2004.07.28.
2	Pacemaker electrode cardiac, implantable	
3	Prosthesis, valve, cardiac, composite	
4	Prosthesis, valve, cardiac, biological	
5	Prosthesis, valve, cardiac, non-biological	
6	Defibrillator, implantable	
7	Infusion pump, electrically-powered, implantable	2007.07.18.
8	Silicone gel-filled breast implants	
9	Implantable defibrillator electrode	2008.12.30.
10	Artificial temporomandibular prosthesis	2012.09.25.
⋮	⋮	⋮

2. Life-supporting medical devices that can be used in places other than medical institutions

	Medical Devices	date
1	low-powered defibrillator	2008.12.30
2	high-powered defibrillator	
3	Patient monitoring system (limited to the ones worn at all times.)	2012.09.25.
4	Prosthesis, valve, cardiac, non-biological	

Detailed information of medical devices subject to tracking(52items) is posted on the website([www.mfds.go.kr/eng](http://www.mfds.go.kr/eng))




## 09. Recalls

### Types of Recall

- ▶ (Firm-initiated Recall) Recall made usually voluntarily by the firm after the discovery of safety issues or product defects that may have potential health risk to patients.
- ▶ (Government-initiated Recall) Recall order made by Minister of MFDS when the product is determined to be defective or potentially harmful.


### Procedure for Government-initiated Recall





# 10. Research Development Project Aimed at Advancing Medical Devices

Safety Control R&D on Medical Devices: 8.073 billion won.



Laying a cornerstone for scientific assessment in line with shifts in future medical environments, as well as with support for expedited commercialization and medical devices safety

- ▶ Research on setting a system and policies for pre and post-market safety management
- ▶ Creation of guidelines and development of tests for assessment of safety and efficiency of medical devices
- ▶ Development of preemptive assessment technologies in support of rapid commercialization of newly-developed convergence products
- ▶ Research on development of Korean standards (KS) and International standards regarding medical devices

## Major Achievements in 2019

- ▶ Creating standards for assessment and management of Clinical Laboratory Authorization Certificate
- ▶ Completing the guideline for quality assessment of automatic hematology analyzer
- ▶ Creating and confirming reference materials for IVD devices
- ▶ Building standard data sets for each disease to ensure the performance and safety of CDSS medical devices
- ▶ Developing standards for smart healthcare convergence products



## List of Reference Materials for IVD Devices

MFDS has steadily secured and distributed the reference standard of IVD for consistent quality.

- ▶ To secure quality reliability of the reference standards, MFDS has conducted the stability test on the reference standards in storage periodically


No	Cat. code	Item name
1	IVD-12/001	Rotavirus plasmid DNA (Mixed Panel)
2	IVD-12/002	Rotavirus RNA
3	IVD-12/003	Rotavirus Antigen (High/Medium/Low concentration)
4	IVD-12/004	Malaria antigen (Mixed titer performance panel)
5	IVD-12/005	Anti-Malaria (Mixed Titer Performance Panel)
6	IVD-12/006	Anti-Syphilis (Mixed Titer Performance Panel)
7	IVD-12/007	HIV-1 RNA (Working Standard)
8	IVD-12/008	HIV-1 DNA (rDNA-derived)
9	IVD-12/009	Group A Streptococcus DNA (High/Medium/Low concentration)
10	IVD-12/010	Group A Streptococcus Antigen (High/Medium/Low concentration)
11	IVD-12/011	Group B Streptococcus DNA (High/Medium/Low concentration)
12	IVD-12/012	Group B Streptococcus Antigen (High/Medium/Low concentration)
13	IVD-12/017	Anti-HAV (Working Standard)
14	IVD-12/018	Anti-HAV (Mixed Titer Performance Panel)
15	IVD-12/019	HBV DNA (Working Standard)
16	IVD-12/020	HBV DNA (rDNA-derived)
17	IVD-12/021	HCV RNA (Working Standard)
18	IVD-12/022	HCV DNA (rDNA-derived)
19	IVD-12/023	Streptococcus Pneumoniae Antigen (High/Medium/Low concentration)
20	IVD-12/024	Streptococcus Pneumoniae DNA (High/Medium/Low concentration)
21	03/010	Hepatitis B virus surface antigen
22	08/023	Human Papilloma Virus L1 DNA
23	08/024	Hepatitis B virus surface antigen (Working Standard)
24	08/029	ABO & D Frozen Red Blood Cell Panel
25	09/031	Anti-HIV 1 (Working Standard)
26	12/038	Anti-HIV 1 (Mixed Titer Performance Panel)
27	12/039	Anti-HIV 1 (Working Standard)
28	IVD-14/001	Hepatitis B virus surface antigen (Low titer performance panel)
29	IVD-14/002	Hepatitis B virus surface antigen (Mixed titer performance panel)
30	IVD-15/001	Anti-HIV 2 (Mixed Titer Performance Panel) (HIV-2/01~06)
31	IVD-15/002	Anti-HIV 2 (Mixed Titer Performance Panel) (HIV-2/07~12)

# 11. Sustainable Effort & Commitment for International Cooperation

Joining of IMDRF as an Management Committee (MC) member and our participations in Work Items (WI)

- ▶ As of December, 2017, Korea officially joined IMDRF as a 10th MC member of International Medical Device Regulators Forum (IMDRF).
- ▶ In order to implement initiatives that are developed by IMDRF and successfully take part in IMDRF as an MC member, MFDS operates the domestic IMDRF steering committee which is composed of experts group from other regulatory authorities, industry, academia or research organizations.
- MFDS is also actively participating in various work items of IMDRF including Medical Device Cybersecurity Guide, Medical Device Clinical Evaluation, Regulated Product Submission, Unique Device Identification, Standards, Adverse Event Terminology, Good Regulatory Review Practices, and Personalized Medical Devices.

Korea will assume the chairmanship of 2021 IMDRF





Your **VISION**,  
Our **FUTURE**  
Korean Medical Device



Ministry of Food and  
Drug Safety

Medical Device Evaluation Department | Cardiovascular Devices Division  
Contact : MD.MFDS@korea.kr Published in 2019 (Ver.3)  
[www.mfds.go.kr/eng](http://www.mfds.go.kr/eng)

187, Osongsaengmyeong 2-ro, Osong-eup, Heungdeok-gu, Cheongju-si,  
Chungcheongbuk-do, Republic of Korea 28159